Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  CVS Health    CVS

CVS HEALTH (CVS)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

CVS Caremark 4th-Quarter Profit Up 2.6% on Higher Sales

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/06/2013 | 02:59pm CET

--Debt refinancing costs weigh on bottom line, but sales broadly higher

--PBM, retail sales each rise, helping CVS report better-than-expected results

--Same-store sales growth exceeds monthly data posted by Walgreen, Rite Aid

(Updates with CEO interview comments, additional background and the latest stock quote, beginning in the first paragraph.)

 
   By John Kell 
 

CVS Caremark Corp.'s (>> CVS Caremark Corporation) fourth-quarter earnings rose 2.6% as debt refinancing costs weighed on the bottom line, somewhat masking a strong performance for the company's pharmacy-benefits-management business and higher retail sales.

The drugstore retailer and PBM has now reported better-than-expected adjusted earnings for four consecutive quarters. Results in the fourth quarter were led by the PBM business, which saw revenue rise 17% to $18.6 billion, aided by new clients added to the network during the 2012 PBM selling season, higher drug costs and growth in the Medicare Part D program.

On the retail side, the top line jumped 5.1% to $16.3 billion as same-store sales grew 4%, growth that exceeds the monthly sales data posted by rivals Walgreen Co. (>> Walgreen Company) and Rite Aid Corp. (>> Rite Aid Corporation) in late 2012. Prescription volume growth was healthy, aided by client wins after Walgreen's contract dispute last year with fellow PBM Express Scripts Holding Co. (>> Express Scripts Holding Co) and stronger demand for flu-related prescriptions.

But CVS said pharmacy same-store sales were stung by higher usage of low-priced generics, which hurts the top line for drug store chains, though those products have a mixed benefit as they command higher margins.

An active flu season has helped drugstore chains somewhat mitigate the top-line dent caused by higher generic penetration, as consumers seek out vaccinations, order prescriptions and buy over-the-counter cough-and-cold medications. CVS Chief Executive Larry Merlo told Dow Jones Newswires that the company saw a "significant uptick" in flu activity by mid-December and strong demand through most of January.

Mr. Merlo said over the past two weeks, CVS has seen the severity of flu cases moderate. Still, the company has administered about 4.8 million flu shots so far this season, above last year's level.

Overall, CVS reported a profit of $1.13 billion, or 90 cents a share, up from $1.1 billion, or 81 cents a share, a year earlier. Excluding debt-related costs and other items, adjusted earnings from continuing operations were $1.14 in the latest quarter. Revenue increased 11% to $31.39 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.10 on revenue of $31.13 billion.

Gross margin expanded to 20.1% from 19.6%.

For the year, CVS now sees adjusted earnings from continuing operations of $3.86 to $4, a view that was lifted by two cents to reflect the debt refinancing.

CVS will face some lofty comparisons in 2013, due to strong demand for generics, particularly in the first half of the year. And after Walgreen inked a contract agreement with Express Scripts starting in September, the company has had some success winning back some customers it lost to competitors during the months-long spat, resulting in some lost business for CVS.

Shares were up 1.5% to $52.50 in premarket trading.

--Tess Stynes contributed to this article

Write to John Kell at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CVS HEALTH
12/14 CVS HEALTH : chief information officer resigns
12/14 CVS HEALTH : Foundation Announces Grant to Increase Access to Provider Education..
12/14 CVS HEALTH : Solera Health Expands Its Board of Directors with the Addition of H..
12/12 CVS HEALTH : 3 Reasons Why Florida Addiction Recovery Center CEO Is Wary Of $77 ..
12/11 CVS HEALTH : 3 Reasons Why Florida Addiction Recovery Center CEO Is Wary Of $77 ..
12/08 CVS expects U.S. Justice Department to handle review of Aetna deal
12/08 CVS HEALTH : A.M. Best Places Credit Ratings of SilverScript Insurance Company U..
12/08 CVS HEALTH : Greg's Pharmacy, Bluffton, will become a CVS Pharmacy
12/07 MYERS INDUSTRIES : Names Chris DuPaul as Group President, Distribution
12/07 CVS HEALTH : Meningitis B Vaccine Available to Students, Faculty and Staff at UM..
More news
News from SeekingAlpha
12/14 The Next 20 Dividend Achievers Absolutely Trounce The Market
12/14 WALGREENS BOOTS ALLIANCE : Trading At A Bargain
12/13 The Value Of Reliability And Why Omega Healthcare Is A Value Trap
12/13 I'm Sticking With CVS And Walgreens, My Last Two Losers
12/11 CVS AND AETNA : The Worst Of Sick-Care Under One Roof
Financials ($)
Sales 2017 184 B
EBIT 2017 9 955 M
Net income 2017 5 255 M
Debt 2017 24 517 M
Yield 2017 2,81%
P/E ratio 2017 14,11
P/E ratio 2018 12,39
EV / Sales 2017 0,52x
EV / Sales 2018 0,49x
Capitalization 71 720 M
Chart CVS HEALTH
Duration : Period :
CVS Health Technical Analysis Chart | CVS | US1266501006 | 4-Traders
Technical analysis trends CVS HEALTH
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 86,1 $
Spread / Average Target 22%
EPS Revisions
Managers
NameTitle
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Chairman
Jonathan C. Roberts Chief Operating Officer & Executive Vice President
David M. Denton Chief Financial Officer & Executive Vice President
Troyen A. Brennan Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
CVS HEALTH-9.24%71 720
WALGREENS BOOTS ALLIANCE-13.55%71 028
EXPRESS SCRIPTS HOLDING CO-0.93%38 836
MCKESSON CORPORATION6.81%32 357
AMERISOURCEBERGEN CORP.9.90%19 296
CARDINAL HEALTH INC-18.72%19 093